Clinical trials: Rivaroxaban
Venous Thrombosis, Neoplasms
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
The goal of the pilot study is to determine if a multicenter prospective cohort study of cancer patients with blood clots associated with catheters is feasible.
- Trial name
- NCT01999179
- Testing
- Heparin, Low-Molecular-Weight, or direct oral anticoagulants
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Medical College of Wisconsin
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study
The proposed research seeks to provide insights on the contemporary epidemiology, treatment, and outcomes of VTE, including examining the uptake of new treatment strategies, the efficacy and safety of different anticoagulant…
- Trial name
- ALTERNATIVE (NCT03292666)
- Testing
- Oral Anticoagulant
- Where
- 2 sites in United States
- Volunteers
- 39,603 people
- Sponsor
- University of California, San Francisco
Venous Thrombosis, Deep Vein Thrombosis
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450…
- Trial name
- NCT00786422
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 16 sites in Australia, Austria and 7 more
- Volunteers
- 25 people
- Sponsor
- Bayer
Venous Thromboembolic Disease, Pulmonary Embolism
CHIPs-VTE Study in Hospitalized Patients With Lung Cancer
Venous thromboembolism (VTE) is a common complication of malignancies, in particular to lung cancer. Patients with lung cancer in surgical and medical departments are at high risk of VTE development.
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism, Deep Venous Thrombosis
- Trial name
- NCT04158973
- Testing
- Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge, Routine VTE prophylaxis in hospital
- Volunteers
- 3,200 people
- Sponsor
- China-Japan Friendship Hospital
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Knee Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01206972
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 33 sites in Japan
- Volunteers
- 302 people
- Sponsor
- Bayer
Atrial Fibrillation
Left Atrial Appendage Occlusion Versus New Oral Anticoagulants for Stroke Prevention in Patients With Non-valvular Atrial Fibrillation
We will compare long-term effectiveness and safety in patients with atrial fibrillation treated with left atrial appendage occlusion versus new oral anticoagulants to prevent ischemic stroke from multicenter registry data
- Trial name
- NCT03108872
- Testing
- left atrial appendage occlusion, New oral anticoagulants
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Sejong General Hospital
Pulmonary Embolism, Thromboembolism
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of…
- Conditions
- Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis
- Trial name
- EinsteinChoice (NCT02064439)
- Testing
- BAY 59-7939, ASA
- Where
- 266 sites in United States, Australia and 29 more
- Volunteers
- 3,365 people
- Sponsor
- Bayer
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
This study is designed to evaluate the efficacy and safety of SHR-2004 injection in preventing postoperative venous thromboembolism in patients undergoing ovarian cancer surgery.
- Trial name
- NCT06220123
- Testing
- SHR-2004, Enoxaparin Sodium Injection; Rivaroxaban Tablets
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Atrial Fibrillation
Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study
The main objective of the study is to assess preferences of Non Valvular Atrial Fibrillation (NVAF) patients towards different options of an anticoagulation treatment.
- Trial name
- X-PRESS (NCT02876718)
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Taiwan
- Volunteers
- 253 people
- Sponsor
- Bayer
Atrial Fibrillation
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial fibrillation (AF) is the most common sustained abnormal rhythm of the heart, affects an estimated 2.5 to 5 million individuals in the US, and can lead to stroke, heart failure, and premature death.
- Trial name
- REACT COM (NCT01706146)
- Testing
- Non-coumadin Oral Anticoagulant
- Where
- 3 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Northwestern University
Liver Cirrhosis
Anticoagulation for Advanced Cirrhotic Patients After TIPS
Recent studies demonstrated that liver cirrhosis was associated with a hypercoagulability state. Besides, bacterial translocation plays an important role in the pathogenesis and complications in patients with decompensated…
- Trial name
- NCT03005444
- Testing
- Rivaroxaban
- Where
- 11 sites in China
- Volunteers
- 254 people
- Sponsor
- Air Force Military Medical University, China
Ischemic Stroke, Stroke, Acute
Monitoring of NOAC Therapy: Standardizing Reference Intervals
This study is aimed to establish reference intervals of NOAC (dabigatran, apixaban and rivaroxaban) in ethnic Chinese patients.
- Conditions
- Ischemic Stroke, Stroke, Acute, Stroke Syndrome, Ischemic
- Trial name
- NCT04611893
- Where
- Hong Kong
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Neoplasms
Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients
The study is designed to compare the efficacy and safety of oral rivaroxaban and subcutaneous low-molecular-weight heparin in preventing femoral venepuncture associated thrombosis among cancer patients.
- Trial name
- NCT03282643
- Testing
- Rivaroxaban 10 MG, Rivaroxaban 20 MG, Low-molecular-weight heparin
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Capital Medical University
Atrial Fibrillation, Stroke
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
The purpose of this study is to compare the efficacy and safety of rivaroxaban with warfarin for the prevention of blood clots in the brain (referred to as stroke) and blood clots in other parts of the body referred to as…
- Conditions
- Atrial Fibrillation, Stroke, Embolism
- Trial name
- NCT00403767
- Testing
- Rivaroxaban, Warfarin
- Where
- 932 sites in United States, Argentina and 42 more
- Volunteers
- 14,269 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anticoagulants and Bleeding Disorders, Surgery
Oral Surgery in Patients Taking Direct Oral Anticoagulants
This study evaluates the incidence of postoperative bleeding after oral surgical procedures in patients taking direct oral anticoagulants and in patients taking vitamin K antagonists.
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage, Dentoalveolar Haemorrhage
- Trial name
- OSDOA (NCT04505475)
- Testing
- Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
- Where
- Serbia
- Volunteers
- 82 people
- Sponsor
- University of Novi Sad
Peripartum Cardiomyopathy, Postpartum
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and…
- Trial name
- REBIRTH (NCT05180773)
- Testing
- Bromocriptine, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban
- Where
- 64 sites in United States
- Volunteers
- 250 people
- Sponsor
- Dennis M. McNamara, MD, MS
Hypotension
Ambulatory Blood Pressure Monitoring in Rivaroxaban Therapy
One in ten patients on rivaroxaban therapy have dizziness and reductions in blood pressure. The investigators intend to monitor the ambulatory blood pressure of such patients in order to assess whether this is a true haemodynamic…
- Trial name
- NCT02539953
- Testing
- Ambulatory blood pressure monitoring
- Where
- United Kingdom
- Sponsor
- King's College Hospital NHS Trust
Ischemic Stroke, Atrial Fibrillation
Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
The Purpose of this open-label randomized controlled multicenter trial is to evaluate the efficacy and safety of mono-drug therapy with oral anticoagulant compared to combination therapy with antiplatelet drug, in ischemic stroke…
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Atherothrombosis
- Trial name
- ATIS-NVAF (NCT03062319)
- Testing
- Oral Anticoagulant, Antiplatelet Drug
- Where
- Japan
- Volunteers
- 321 people
- Sponsor
- National Hospital Organization Osaka National Hospital
Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
The purpose of this study is to test any good and bad effects of the study drug called PEGPH20. PEGPH20 alone is considered investigational.
- Trial name
- NCT02921022
- Testing
- Gemcitabine, Nab-paclitaxel, PEGPH20
- Where
- 10 sites in United States
- Volunteers
- 110 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nonvalvular Atrial Fibrillation
Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) across risk…
- Trial name
- NCT03374540
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- United States
- Volunteers
- 78,517 people
- Sponsor
- Bayer